Home » Newsletters » BioWorld Science

BioWorld Science

July 25, 2013

View Archived Issues

Molecular InSight Pharmaceuticals prepares novel rhenium complexes

U.S. team discovers new monoacylglycerol lipase inhibitors

Reversal of apixaban anticoagulation with PRT-064445 in phase II study detailed

Transition Therapeutics licenses candidate for osteoarthritis pain from Lilly

Enrollment begins in phase II LGX-818 melanoma trial

FDA approves use of Hologic's Aptima HPV assay on fully automated Panther system

New Alzheimer's disease model is based on N-truncated Abeta4-42 expression

FDA accepts for review Merck & Co.'s vorapaxar NDA for secondary complications

Sarepta plans eteplirsen NDA submission

NOXXON's phase IIa study in diabetic nephropathy now fully enrolled

Reversal of oral anticoagulant activity with PER-977 described

Galectin begins dosing in phase I trial of GR-MD-02

Questcor to commence screening for phase II study of H.P. Acthar Gel in ALS

FDA grants orphan drug designation to Verastem's defactinib in mesothelioma

Fred Hutchinson Cancer Research Center receives National Cancer Institute grant

FDA advisory committee votes in favor of Cimzia for active axial spondyloarthritis

Northeastern University discloses new CB1 receptor modulators

Valproic acid analogue evaluated for antimigraine potential

InhibOx receives grant to develop novel therapies for multidrug-resistant infections

Allergan prepares new sodium channel blockers

Researchers at Complix patent novel polypeptides for cancer

Health Canada approves two GSK drugs for metastatic melanoma

Akebia Therapeutics commences phase IIb trial of oral HIF-PH inhibitor for anemia

New agents for tuberculosis synthesized by CSIR

Scientists at BioAlliance divulge new murine/human antibodies targeting TfR

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...